Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05429840 | Safety & PK of Single Doses of MT1980 | PHASE1 | COMPLETED | 24 | — | — | Jun 1, 2022 | Oct 4, 2022 | Nov 2, 2022 | 1 | Netherlands |
Descriptive statistics comparing MT1980 \& placebo following a single dose of study drug. Number of subjects, number of events and severity of events to be reported
| Arm | Type | Description |
|---|---|---|
| Part 1 MT1980 | EXPERIMENTAL | - |
| Part 1 Placebo | PLACEBO_COMPARATOR | - |
| Part 2 MT1980 Dose Level 1 | EXPERIMENTAL | - |
| Part 2 MT1980 Dose Level 2 | EXPERIMENTAL | - |
| Part 2 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MT1980 | DRUG | single dose |
| Placebo | DRUG | single dose |
Inclusion Criteria: * Healthy volunteers with good physical and mental health * Body Mass Index 18 to 30 kg/m2 * Men \& women of child-bearing potential must agree to use adequate contraception * Willing \& able to provide written informed consent and to communicate and participate in the study Ex...